Eli Lilly Oncology — Revenue increased by 8.3% to $2.61B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 2.2%, from $2.55B to $2.61B. Over 4 years (FY 2021 to FY 2025), Oncology — Revenue shows an upward trend with a 13.0% CAGR.
lly_segment_oncology_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.55B | $1.41B | $1.41B | $1.35B | $1.37B | $1.29B | $1.65B | $1.36B | $1.67B | $1.75B | $1.88B | $1.81B | $2.16B | $2.23B | $2.55B | $1.95B | $2.41B | $2.41B | $2.61B |
| QoQ Change | — | -9.5% | +0.2% | -4.0% | +1.2% | -5.5% | +27.7% | -17.9% | +23.2% | +4.6% | +7.8% | -3.9% | +19.3% | +3.4% | +14.3% | -23.7% | +23.9% | -0.2% | +8.3% |
| YoY Change | — | — | — | — | -11.9% | -8.0% | +17.2% | +0.2% | +22.1% | +35.1% | +14.1% | +33.5% | +29.2% | +27.7% | +35.4% | +7.6% | +11.8% | +7.9% | +2.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.